1-es típusú cukorbetegség: vizsgálatok itt: Norvégia
1 of 4 trials · From ClinicalTrials.gov, checked 2026. november 19.. Ask the study team whether a trial fits you.
- No phaseTaking peopleA Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Where
- Bergen
- Életkor
- 18 év to 99 év
- People
- 24 000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05663515